{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-005695","form_type":"8-K","ticker":"VTAK","cik":"0001716621","company_name":"Catheter Precision, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.714433+00:00","generated_at":"2026-06-02T19:11:40.480376+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Catheter Precision Q1 2024 revenue $82K, net loss $2.7M; cash drops to $0.5M","bullets":["Q1 2024 revenue of $82,000; net loss of $2.7 million.","Cash decreased from $1.5M (Mar 31) to $0.5M (May 6, 2024).","LockeT submitted for CE Mark approval, expected Q3 2024; initial clinical data positive.","Appointed Marie-Claude Jaques as Chief Commercial Officer effective May 1, 2024.","Company is seeking additional financing to pursue business objectives."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-005695","json":"https://secwatch.observer/filing/0001654954-24-005695.json","markdown":"https://secwatch.observer/filing/0001654954-24-005695.md","text":"https://secwatch.observer/filing/0001654954-24-005695.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424005695/0001654954-24-005695-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424005695/rmed_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:11:40.480376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d22331c7225535b0038da9ee6bfe57c010850187","claim":"Catheter Precision, Inc. reported the quarter ended March 31, 2024 results: revenue $82 thousand, net income ($2.7) million.","evidence_excerpt":"were $28 million · Total cash on position at March 31, 2024 was $1.5 million, and $0.5 million at May 6, 2024 · Total revenues for the three months ended March 31, 2024 were $82 thousand · Shareholders’ equity as of March 31, 2024 was $18.5 million · Net loss for the quarter ended March 31, 2024 was ($2.7) million · All revenue as of March 31, 2024 resulted from","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424005695/0001654954-24-005695-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$82 thousand"},{"label":"Net income","value":"($2.7) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}